ArticleCureus2025
KRAS and NRAS Mutations in Relation to Microsatellite Status in Colorectal Cancer: A Single-Center Study From Romania.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Co-Occurrence of Nuclear-Catenin and H3K27me3 Expression in Advanced Colorectal Cancer: A Retrospective Observational Study.Current oncology (Toronto, Ont.) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives Colorectal cancer is one of the most prevalent malignancies worldwide, ranking third globally and second in Romania. This study aimed to investigate the coexistence of microsatellite instability (MSI) status with KRAS and NRAS mutations in colorectal cancer patients. Methods We analyzed clinicopathological characteristics in 253 patients diagnosed with colorectal cancer between January 1, and June 30, 2024. Polymerase chain reaction (PCR) techniques were used to assess MSI status and detect KRAS and NRAS mutations. Results Among the 253 patients, KRAS mutations were detected in 41.1%, while NRAS mutations were identified in 5.1% of cases. Microsatellite stability (MSS) was observed in the majority of cases (95.7%), with only 4.3% of tumors displaying high microsatellite instability (MSI-H). Of all the analyses undertaken to evaluate associations between clinicopathological characteristics of patients with colorectal cancer and KRAS/NRAS or MSS/MSI-H status, tumor localization demonstrated a statistically significant correlation with microsatellite status (p = 0.032). Conclusions The prevalence of KRAS and NRAS mutations in the studied population was consistent with international estimates, whereas the frequency of MSI-H tumors was lower compared to other European cohorts. A statistically significant association was observed between tumor localization and MSI status (p = 0.032), with MSI-H tumors confined to colonic sites and MSS tumors predominating in the rectum. These data refine the molecular epidemiological landscape of colorectal cancer in an under-studied population and underscore the necessity of larger multicenter investigations to validate and extend these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.